The Hidradenitis Suppurativa (HS) Treatment Market is anticipated to increase at a CAGR of 4.97% from its outstanding valuation of US$ 763.6 million in 2023 to US$ 1,240.9 million by 2033. The market for hidradenitis suppurativa now has a large pipeline of treatments that target interleukins, such as IL-17 and IL-1, anti-TNF, JAKi, and anti-complement factor. Future treatments for hidradenitis suppurativa are anticipated to have an easy-for-the-patient mode of administration and to prolong the course of treatment, both of which will raise market demand.
A significant driver of market expansion is the rise in the incidence of skin diseases (UI). The development of hidradenitis suppurativa is also aided by secondary infection, hair follicle blockage, and irritation of certain sweat glands. The rising cost of healthcare, which aids in improving its infrastructure, is another important element driving the hidradenitis suppurativa market’s rise. The market for hidradenitis suppurativa will also grow as a result of rising awareness-raising campaigns by both public and private organisations and an increase in obesity incidence. Moreover, the market for hidradenitis suppurativa will expand due to increased disposable income and shifting consumer lifestyles. In addition, a growing elderly population and rising smoking rates will boost market expansion.
Request Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-16512
A rise in the quantity of R&D activities is another factor driving the market’s expansion. The market for hidradenitis suppurativa will benefit from these lucrative potential. Future technologically advanced therapies including laser surgery are projected to drive the hidradenitis suppurativa market’s expansion.
The market for hidradenitis suppurativa is also expanding as a result of FDA approvals for drug delivery and clinical trials. Increased drug releases and approval rates, as well as an increase in the number of emerging markets, will all help the hidradenitis suppurativa market grow over the projection period.
Key Takeaways from the Market Study
- North America is expected to dominate the market of hidradenitis suppurativa treatment with market valuation to reach USD 620.4 million by end of the forecast period.
- The market in East-Asia is anticipated to record fastest CAGR of 5.1% during the projected timeline.
- By treatment type, biologics segment is expected is to lead the market with 61.4% segment share by end of 2033.
- With market share of 65%, hospital pharmacy is expected to possess market hegemony by distribution channel, by end of the forecast period.
Ask An Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-16512
“Technologically sophisticated treatments like laser therapy and rapid drug approvals will fuel the market in forecast period”, comments an FMI analyst.
Competitive Landscape
The global Hidradenitis suppurativa market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition. Some recent developments in this industry are as follows:
- In June 2022, Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus were announced by Roivant and Pfizer.
- In February 2021, AbbVie Inc., received FDA approval for HUMIRA (adalimumab), which can be used to treat moderate to severe hidradenitis suppurativa.
- In March 2022, MoonLake had started the Phase II trial of nanobody, sonelokimab for treating moderate-to-severe hidradenitis suppurativa (HS). Sonelokimab has the potential to treat inflammatory diseases by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that cause inflammation in the body.
More Valuable Insights Available
Future Market Insights offers an unbiased analysis of the global hidradenitis suppurative (HS) treatment market, providing historical data for 2018-2022 and forecast statistics from 2023-2033.
Request Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-16512
To understand opportunities in the Hidradentitis suppurativa treatment market, the market is segmented on the basis of Clinical stages (Hurley Stage 1-low, Hurley Stage 2-moderate, Hurley Stage 3-high) By Treatment type [(Medication- Biologics, Antibiotics, Hormonal therapy, Immune suppurativa drugs, Zinc supplements, Pain medications), Surgery] By route of administration (Oral, tropical) By end-user (Hospitals, homecare, Specialty clinics) By distribution channel (Hospital Pharmacy, retail pharmacy, online pharmacy) By region (North America, Latin America, Europe, South-Asia, East-Asia, Oceania, Middle East, and Africa)
Key Companies Profiled
- InflaRx N.V
- Novartis A.G
- Incyte Corporation
- UCB Biopharma SPRL
- Janssen Pharmaceuticals
- Amgen Inc.
- ChemoCentryx
- Priovant Therapeutics
- AnaptysBio
- AbbVie Inc.
- ACELYRIN
- Aclaris Therapeutics Inc.
Key Segments Profiled in the Hidradenitis Suppurativa (HS) Treatment Market Industry Survey
By Clinical Stages:
- Hurley Stage 1- Low
- Hurley Stage 2- Moderate
- Hurley Stage 3- High
Use promo code >> FMITODAY to get flat 20% discount
By Treatment Type:
- Medication
- Biologics
- Antibiotics
- Hormonal Therapy
- Immune Suppurativa Drugs
- Zinc Supplements
- Pain Medications
- Surgery
By Route of Administration:
- Oral
- Tropical
By End Users:
- Hospitals
- Homecare
- Specialty Clinics
By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Top Related Reports:
Molecular Quality Controls Market
Enteral Feeding Devices Market
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports